Iovance Biotherapeutics (IOVA) EBT Margin (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly EBT Margin of 111.59% for Q1 2026, up 12764.0% year-over-year from N/an in Q1 2025, and down 35.01% quarter-over-quarter from 82.65% in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) EBT Margin (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported EBT Margin for 4 consecutive years, with 111.59% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 12764.0% year-over-year to 111.59%; the TTM figure through Mar 2026 stood at 124.21% (up 5381.0% YoY), while the FY2025 annual figure was 149.16%, up 7940.0% from the prior year.
- EBT Margin retreated to 111.59% in Q1 2026 per IOVA's latest filing, from 82.65% in the prior quarter.
- Across five years, EBT Margin topped out at 82.65% in Q4 2025 and bottomed at 44960.08% in Q2 2023.
- Historically, EBT Margin has averaged 9275.88% across 4 years, with a median of 211.08% in 2025.
- Annual changes were most pronounced in 2024 — EBT Margin jumped 4464324 bps — and 2025, when it jumped 642 bps.
- Iovance Biotherapeutics' EBT Margin stood at 24509.96% in 2023, then soared by 100 bps to 104.49% in 2024, then climbed by 21 bps to 82.65% in 2025, then plunged by 35 bps to 111.59% in 2026.
- Business Quant data shows IOVA's EBT Margin at 111.59% in Q1 2026, 82.65% in Q4 2025, and 138.85% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | -49.02% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -49.02% |
| Mar 31, 2026 | -111.59% |
| Dec 31, 2025 | -82.65% |
| Sep 30, 2025 | -138.85% |
| Jun 30, 2025 | -182.93% |
| Mar 31, 2025 | -239.24% |
| Dec 31, 2024 | -104.49% |
| Sep 30, 2024 | -145.27% |
| Jun 30, 2024 | -316.85% |
| Mar 31, 2024 | -15,997.76% |
| Dec 31, 2023 | -24,509.96% |
| Sep 30, 2023 | -24,520.90% |
| Jun 30, 2023 | -44,960.08% |